FirsthandHealth
medRxiv PreprintsInternational18 November 2026

Genetically Proxied NLRP3 Inflammasome Downregulation and Cardiovascular Disease

This is an official announcement record

Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.

Background: The inhibition of NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome is an emerging therapeutic strategy for atherosclerotic cardiovascular disease (ASCVD). Although early clinical trials demonstrate reductions in inflammatory biomarkers, whether these translate into cardiovascular benefit remains uncertain. We investigated the potential efficacy and safety of NLRP3 inhibition using human genetics. Methods: We developed a cis-genetic instrument for NLRP3 downregulation using C-reactive protein (CRP) associated variants (P<5 x 10^-8) within the NLRP3 locus (+/-100
Source: medRxiv Preprints
Read the official announcement

Opens www.medrxiv.org

More from medRxiv Preprints

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.